Multi-Agitator System for Mixing and Dispersion Requirements

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2017
Volume 41
Issue 10
Pages: 14

Ross, Charles & Son’s VersaMix is a multi-shaft mixer designed for viscous applications requiring a high level of accuracy and batch-to-batch consistency.

Ross, Charles & Son’s VersaMix is a multi-shaft mixer designed for viscous applications requiring a high level of accuracy and batch-to-batch consistency. The mixer consists of two or three independently-driven agitators working in tandem to ensure high-speed fine dispersion, efficient turnover, and uniform heating/cooling. 

The VMC-200 model has a maximum working capacity of 200 gallons. An air/oil lift raises and lowers the agitators into the vacuum-rated vessel. All product contact surfaces are stainless-steel type 316L polished 180-grit finish. The ASME 60-psi jacket on the vessel is insulated with two-inch thick mineral wool and sheathed with water-tight stainless-steel cladding.

Equipped with a 10HP anchor agitator, 20HP disperser, and 25HP rotor/stator, the mixer delivers a combination of laminar bulk flow and intensity necessary for homogenization and deagglomeration in high-viscosity conditions up to several hundred thousand centipoises. The vacuum cover includes multiple charging ports, viewing windows, tank light, and a thermoprobe. Finished product is discharged out of a three-inch pneumatically-actuated diaphragm valve installed on the tank’s conical bottom.

Available in standard sizes from 1- to 4000-gallon capacity, the mixer offers simple and reliable scalability from product development to full-scale production. Mixer features are tailored to a specific formulation or range of products for maximum functionality. 

Ross, Charles & Son

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content